74th Day Of Lockdown

Maharashtra80229286942849 Tamil Nadu2869415762235 Delhi2633410315708 Gujarat19119130111190 Rajasthan100847359218 Uttar Pradesh97335648257 Madhya Pradesh89965878384 West Bengal73032912366 Karnataka4835169357 Bihar4598223329 Andhra Pradesh4250256573 Haryana3597120924 Telangana32901627113 Jammu and Kashmir3142104835 Odisha247814819 Punjab2415204347 Assam19894434 Kerala170071215 Uttarakhand115328610 Jharkhand7642975 Chhatisgarh6781892 Tripura6221730 Himachal Pradesh3691636 Chandigarh3022225 Goa126570 Manipur124110 Puducherry90330 Nagaland8000 Arunachal Pradesh3710 Meghalaya33131 Mizoram1710 Sikkim200
Business Companies 08 Jan 2018 Eight Chinese compan ...

Eight Chinese companies get notices for poor quality of APIs

DECCAN CHRONICLE.
Published Jan 8, 2018, 1:50 am IST
Updated Jan 8, 2018, 1:50 am IST
The allegations against the companies are of providing poor quality products.
The Central government has issued showcause notices to eight Chinese pharmaceutical firms for supplying poor quality raw material to Indian drug makers.
 The Central government has issued showcause notices to eight Chinese pharmaceutical firms for supplying poor quality raw material to Indian drug makers.

Hyderabad: The Central government has issued showcause notices to eight Chinese pharmaceutical firms for supplying poor quality raw material to Indian drug makers, said a news agency, adding that these companies may be blacklisted.

“The allegations against the companies are of providing poor quality products and the action against them will soon be decided by the government. This will be harsh as we don’t want the quality of drugs in India compromised,” said IANS quoting a senior DCGI officer. “The notices were issued after a special inspection team of the Drug Controller General of India (DCGI) inspected the eight companies in China,” it said.

 

Most Indian pharma firms are of late depending on active pharmaceutical ingredients (API) or raw material for medicine from Chinese companies, raising concern in the Indian government.

According to a pharma industry body, Indian pharma companies secure 70-75 percent of APIs from China. India typically imported around `12,000 crore worth APIs every year from China. However, this figure had risen to `18,372.54 crore in FY17.

The Indian drug makers have shifted to Chinese APIs as they were about four times cheaper than those produced in India. The Chinese companies manufacture in large scale and have cheaper power, helping them to cut down on the cost.

Calling it a bold decision by the government, Dr Appaji, former director-general of Pharmexil, said, “Though it sends a signal to importers that we are vigilant about the quality of drugs, the government should be extremely careful and cautious to ensure that it does not lead to supply disruption.”

He said the Centre should also take care of the Indian pharma industry’s needs by promoting domestic APIs, which are cost-effective. Last year, the government had proposed to give preference to formulations produced from indigenous API and its intermediates in government procurements.

...




ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT